Novartis (NYSE:NVS) Stock Sale Reported by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Novartis stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novartis Price Performance

Shares of Novartis stock traded down $1.69 on Tuesday, hitting $145.19. The company’s stock had a trading volume of 896,428 shares, compared to its average volume of 1,995,388. The company has a market capitalization of $277.04 billion, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 2.81 and a beta of 0.45. Novartis AG has a 1 year low of $121.57 and a 1 year high of $170.46. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a fifty day moving average price of $151.62 and a 200-day moving average price of $151.15.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. As a group, sell-side analysts anticipate that Novartis AG will post 8.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on NVS shares. The Goldman Sachs Group reaffirmed a “sell” rating on shares of Novartis in a research note on Monday, September 21st. HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and raised their price objective for the company from $123.00 to $136.00 in a report on Thursday, September 10th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Berenberg Bank decreased their price target on shares of Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a research note on Friday, September 11th. Finally, Sanford C. Bernstein restated a “neutral” rating on shares of Novartis in a research report on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $148.40.

Institutional Trading of Novartis

Hedge funds have recently made changes to their positions in the company. QRG Capital Management Inc. raised its position in Novartis by 9.0% in the second quarter. QRG Capital Management Inc. now owns 164,478 shares of the company’s stock valued at $25,777,000 after purchasing an additional 13,634 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in Novartis by 3.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 19,022 shares of the company’s stock valued at $2,981,000 after buying an additional 713 shares during the period. Envestnet Asset Management Inc. lifted its position in Novartis by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock valued at $365,308,000 after buying an additional 19,595 shares during the last quarter. Silicon Valley Capital Partners boosted its stake in Novartis by 519.4% during the second quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after buying an additional 161 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Novartis in the 2nd quarter valued at approximately $4,529,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.